30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Opportunity in Value-Based Care Lies in Impacting Quality

The mid- to long-term future will require increased evidence to support pricing and value by device companies. It can be contended that broader thinking and strategic response around quality might actually create opportunities for sustained and growing market share for OEMs, as well as greater value for customers—hospitals, physicians and patients.

OMTEC Recap: Orthopedic Surgeons Waiting for Technology to Catch Up to Their Needs

Surgeons were clear: they are interested in leveraging innovations in materials, robotics, AI and wearables for the benefit of their patients and their practices. They will look to the data to measure progress.

Market Insight: Trauma Needs Products that Improve Efficiency, Gain Traction Quickly

The trauma market is largely driven by the need to repair fractures in the hips and upper extremities. In recent years, it has attracted established players from other orthopedic subsegments that seek to diversify their portfolios, startups with novel technology and numerous players focused specifically on foot and ankle. We spoke with David Kay, M.D., a foot and ankle surgeon and orthopedic device entrepreneur, to gain his perspective on current and future factors affecting the trauma market. His comments originally appeared in THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT®.

Market Insight: Orthobiologic Products Must Become Procedure-Specific

Orthobiologics plays a role in every orthopedic market segment; the importance of its advancements affects the industry as a whole. We asked Andy Carter, Ph.D., Chief Technology Officer at TheraCell, to give his insight on the orthobiologics market—as it stands now, and where it’s heading in the near future. His comments originally appeared in ORTHOWORLD’s Annual Report.

The Spine Market: A Look at Past and Forecasted Performance

Spine is the largest individual segment that we track, accounting for 18.2% of the orthopedic industry’s overall revenue. Excluding biologics, sales of orthopedic spine products topped $9.3 billion in 2018, growing +2.7% vs. 2017. Growth in the segment exceeded our expectations, as several companies in the top 10 posted double-digit increases that offset lower performance by manufacturers at the top of the list.

Here, we take a deeper look at past, present and forecasted performance.

Page Navigation